EFTA00589347Set 9
2012-11-203p1,134w
NeuroVive"
NEWS RELEASE
NeuroVive and Sihuan Pharmaceutical to develop and commercialize
CicloMulsion® and NeuroSTAT® for cardio- and neuroprotection in China
Beijing (China) and Lund (Sweden) - November 20, 2012. NeuroVive ... development and commercialization in China of
NeuroVive's most clinically advanced products CicloMulsion® and NeuroSTAT®.
Sihuan Pharmaceutical is one of the largest domestic pharmaceutical companies in China
and the market ... normal regenerative mechanisms can act to
repair and maintain the cell. CicloMulsion® and NeuroSTAT® contain cyclosporine which, by
inhibiting cyclophilin D, prevents the disruption of the membrane of the mitochondria
https://www.justice.gov/epstein/files/DataSet%209/EFTA00589347.pdf
EFTA01113072Set 9
2012-11-203p1,137w
NeuroVive"
NEWS RELEASE
NeuroVive and Sihuan Pharmaceutical to develop and commercialize
CicloMulsion® and NeuroSTAT® for cardio- and neuroprotection in China
Beijing (China) and Lund (Sweden) - November 20, 2012. NeuroVive ... development and commercialization in China of
NeuroVive's most clinically advanced products CicloMulsion® and NeuroSTAT®.
Sihuan Pharmaceutical is one of the largest domestic pharmaceutical companies in China
and the market ... normal regenerative mechanisms can act to
repair and maintain the cell. CicloMulsion® and NeuroSTAT® contain cyclosporine which, by
inhibiting cyclophilin D, prevents the disruption of the membrane of the mitochondria
https://www.justice.gov/epstein/files/DataSet%209/EFTA01113072.pdf
EFTA00668688Set 9
2012-11-284p1,496w
Steve Campbell
NEWS RELEASE
NeuroVive and Sihuan Pharmaceutical to develop and commercialize CicloMulsion° and
NeuroSTAT° for cardio- and neuroprotection in China
Beijing (China) and Lund (Sweden) - November 20, 2012. NeuroVive ... specifically the work
we have done to develop the cyclophilin inhibitors CicloMulsion® and NeuroSTAT®. Sihuan is one of the leading
pharmaceutical companies in China and through this agreement will ... product resources and widen our revenue
stream. We believe that CicloMulsions and NeuroSTAT" will become new drivers of our sales, sustain our growth in the
long run, and consolidate Sihuan
https://www.justice.gov/epstein/files/DataSet%209/EFTA00668688.pdf
EFTA00937845Set 9
2012-06-192p777w
approval) of their cyclophilin inhibitors.
NeuroVive's cyclopsorine-based traumatic brain injury pharmaceutical, called NeuroSTAT, reduces brain damage
in animals by 80%.
One magazine called cyclosporine "TBI's Miracle Drug ... headline was the editor's). It explains why
inhibiting cyclophilins are so important.
EFTA00937845
NeuroSTAT is in phase II/III adaptive clinical study in Europe. Adaptive means it will be converted ... could help by driving funding to start and speed up US clinical studies for NeuroSTAT. To get it approved
closer to two years, rather than the projected five. The Foundation
https://www.justice.gov/epstein/files/DataSet%209/EFTA00937845.pdf